What is the current size of the biopsy guidance systems market?

The market size of biopsy guidance systems in 2027 is calculated to be USD 1.26 billion.

How is the biopsy guidance systems industry size expected to evolve during the forecast period?

Biopsy Guidance Systems Market size stood at USD 1.2 billion in 2026 and is predicted to grow at a 5.8% CAGR from 2027 to 2036, exceeding USD 2.11 billion by 2036.

How is rising cancer incidence influencing adoption of biopsy guidance systems?

Increasing cancer cases are driving demand for minimally invasive, image-guided biopsy procedures that improve lesion targeting accuracy, support outpatient workflows, reduce repeat sampling, and enhance diagnostic efficiency in complex anatomical cases.

How are imaging advances and screening programs strengthening demand for biopsy guidance systems?

Advances in 3D imaging and stereotactic technologies improve lesion localization and sampling precision, while expanded screening programs increase early detection volumes, requiring faster diagnostic workflows and higher-capacity guided biopsy systems in clinical settings.

Why does brain biopsy hold the largest share of the biopsy guidance systems market?

Brain Biopsy leads the market because procedures require highly accurate navigation for complex anatomical structures, making precision guidance essential for reliable tissue sampling and effective risk management.

Why is ultrasound-guided biopsy the fastest-growing product segment in the biopsy guidance systems market?

Ultrasound Guided Biopsy is growing fastest because real-time imaging supports efficient needle placement, improves procedural flexibility, and integrates easily into expanding image-guided clinical workflows across care settings.

What makes North America the leading market for biopsy guidance systems?

North America accounted for a 48.12% market share in 2026, supported by advanced diagnostic imaging infrastructure, integrated clinical workflows, and routine use of image-guided biopsy procedures.

What factors are accelerating growth in the Asia Pacific biopsy guidance systems market?

Asia Pacific is projected to grow at a 7.01% CAGR as hospital investments, wider access to imaging technologies, and expanding cancer detection services increase demand for guided biopsy systems.

Who are the leading players in the biopsy guidance systems landscape?

Leading players in the biopsy guidance systems market include Hologic, Inc. (United States), Becton, Dickinson and Company (United States), Boston Scientific Corporation (United States), Cook Medical LLC (United States), B. Braun Melsungen AG (Germany), Argon Medical Devices, Inc. (United States), Devicor Medical Products, Inc. (United States), Planmed Oy (Finland), INRAD, Inc. (United States), Siemens Healthineers AG (Germany).